Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Authors:
Open Access
- 1 November 2022
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (11) , 1254-1261
Abstract
Atopic dermatitis (AD) is a prevalent inflammatory dermatosis with increasing worldwide prevalence.1,2 Symptoms, such as relapsing pruritus and visible lesions, may last for a few years and even persist throughout life, necessitating effective treatments.3,4 Janus kinase (JAK) inhibitors have become a promising treatment option for patients with AD because they have been associated with favorable clinical outcomes in clinical trials.5Keywords
This publication has 59 references indexed in Scilit:
- Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational StudiesJournal of the American Heart Association, 2013
- Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activationInflammation Research, 2012
- Plasma platelet activation markers in patients with atopic dermatitis and concomitant allergic diseasesJournal of Dermatological Science, 2011
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular EventsJAMA, 2011
- Association between atopic diseases and venous thromboembolism: a case–control study in patients aged 45 years or lessJournal of Thrombosis and Haemostasis, 2011
- Elevated Platelet Activation in Patients with Atopic Dermatitis and Psoriasis: Increased Plasma Levels of β-Thromboglobulin and Platelet Factor 4Allergology International, 2008
- Tryptase genetics and anaphylaxisJournal of Allergy and Clinical Immunology, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Risk Factors for Venous ThromboembolismCirculation, 2003
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000